Valion Bio (VIBO) investor relations material

Executive summary

• Completed corporate transformation and rebranding to Valion Bio, integrating Velocity Bioworks and focusing on clinical-stage biopharmaceuticals anchored by Entolimod, a TLR5 agonist with FDA Fast Track and Orphan Drug designations.

• Acquired Scorpius Holdings' CDMO assets, vertically integrating manufacturing and expanding into contract services, with Velocity Bioworks operational and providing immediate and future revenue potential.

• Advanced Entolimod platform with broader U.S. government engagement for ARS countermeasures and continued development of Entolasta for oncology supportive care.

• Appointed Michael K. Handley as CEO and Melinda Lackey as General Counsel in 2026 to support legal and strategic growth.

• Strategic focus on both government medical countermeasures and commercial oncology supportive care markets.

Financial highlights

• Total operating expenses for Q1 2026 were $5.6 million, up from $1.4 million in Q1 2025, driven by Velocity Bioworks integration, R&D, and rebranding expenses.

• Net loss for Q1 2026 was $6.2 million ($2.23/share), compared to $1.5 million ($2.52/share) in Q1 2025.

• Cash and cash equivalents at March 31, 2026 were $7.2 million, down from $12.6 million at year-end 2025.

• Accumulated deficit reached $59.0 million as of March 31, 2026.

• Working capital was $5.3 million at quarter-end.

Outlook and guidance

• Physician-sponsored studies in neutropenia expected to begin in H2 2026, with six institutional sites interested.

• Entolimod GMP manufacturing validation to start in Q3 2026, targeting completion by year-end, and pre-BLA meetings planned for Q4 2026.

• Ongoing NIAID-funded BLA enabling testing and continued government engagement throughout 2026.

• Velocity Bioworks to scale third-party CDMO customer engagement, aiming for near-term revenue, though no material revenues expected until facilities are fully qualified.

• Expects continued significant operating losses and anticipates need for substantial additional capital within the next twelve months.